Drug
Desidustat
Desidustat: highest development phase Post-Market, developed by Zydus. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Zydus
Trials
| Drug | Phase | Indication |
|---|---|---|
| Desidustat NCT05515367 | Post-Market | Chronic Kidney Diseases |
| Desidustat Oral Tablet NCT04215120 | Phase 3 | Chronic Kidney Disease Stage 5 on Dialysis |
| Desidustat NCT04463602 | Phase 2 | COVID-19 |
| Desidustat NCT04667533 | Phase 1 | Anemia of Chronic Kidney Disease |
Latest
Follow Desidustat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.